Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

The following table summarizes information about the Company’s stock options outstanding at June 30, 2016, and activity during the six month period then ended:

					Weighted-
					Average
			Weighted-		Remaining
			Average		Contractual		Aggregate
	Stock Awards		Exercise Price		Life (Years)		Intrinsic Value
Balance as of December 31, 2015		1,963	$	7.09
Options granted		492	$	6.30
Options exercised		(18)	$	3.16
Options forfeited		(120)	$	8.41
Options cancelled		(14)	$	8.66
Balance as of June 30, 2016		2,303		6.87		7.66	$	815
Vested and expected to vest at June 30, 2016		2,143				7.54	$	815
Exercisable as of June 30, 2016		1,135				6.14	$	804

Schedule of Fair Value Calculation Assumptions

The per-share fair value of each stock option was determined on the date of grant using the Black-Scholes option pricing model using the following assumptions:

	Three months ended June 30,		Six months ended June 30,
	2016	2015	2016	2015

Dividend yield	—	—	—	—
Risk-free interest rate	1.28% - 1.43%	1.44% - 2.34%	1.24% - 1.78%	1.41% - 2.34%
Expected term (in years)	5-6	6-10	5-10	6-10
Volatility	78%	73% - 74%	78%	73% - 74%

Allocation of Stock Option Compensation Expense

Total stock-based compensation expense related to options granted to employees and non-employees was included in the condensed consolidated statements of operations and comprehensive loss as follows:

	Three months ended June 30,				Six months ended June 30,
	2016		2015		2016		2015
Sales and marketing	$	206	$	161	$	438	$	292
Research and development		141		108		372		162
General and administrative		180		174		1,291		337
	$	527	$	443	$	2,101	$	791